Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China

  1. Dong Chen
  2. Xiaokun Li
  3. Qifa Song
  4. Chenchan Hu
  5. Feifei Su
  6. Jianyi Dai
  7. Yinghai Ye
  8. Jianping Huang
  9. Xiaoming Zhang

Reviewed by

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1001/jamanetworkopen.2020.11122
  2. ScreenIT

    SciScore for 10.1101/2020.02.27.20028530: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: This study was approved by the Ethics Committee of Wenzhou Central Hospital and Sixth People’s Hospital of Wenzhou and followed the Declaration of Helsinki.
    Consent: Written consent was acquired for all patients.
    RandomizationWe also randomly selected several clinically mild and severe cases with hypokalemia to trace the treatment effect of K+ supplements.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    All analyses were conducete by SPSS (version 20.0).
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    The present study had some limitations. Most patients were still hospitalized. Only a small proportion of cases were used to evaluate the treatment outcomes. However, from several patients who had been cured, the principal results related to hypokalemia treatment were consistent, which could provide reliable information. Since this life-threatening disease is still ongoing in China and is developing in several countries, we expect our findings can provide timely information about better understanding and treatment of COVID-19. To summarize, the present study has identified the prevailing hypokalemia in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal loss of potassium resulting from the degradation of ACE2 by the binding of SAR-CoV-2. The end of loss of K+ often indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker that reflects the end of adverse effect on the RAS system by SAR-CoV-2. Due to the possible injury to cardiovascular functions, neurohormonal activation, and other vital organs by hypokalemia, clinicians should pay great attention to hypokalemia and the patients’ response to K+ supplements.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.02.27.20028530 on medRxiv